
Waters (WAT) Stock Forecast & Price Target
Waters (WAT) Analyst Ratings
Bulls say
Waters is poised for growth following their recent merger with Becton Dickinson's life science and diagnostics business. This acquisition has increased their concentration in diagnostics and discovery-related life science tools, and their analytical instruments are essential in developing and manufacturing products such as mRNA vaccines. Along with a strong product refresh and a potential for industry consolidation, Waters' financial flexibility, strong management team, and focus on sustainability position them well for future success.
Bears say
Waters is trading at a relatively high P/E ratio compared to its peers, and while the company has a strong organic growth outlook, there are concerns about its ability to effectively manage and integrate the recently acquired Becton Dickinson assets. With a potential slowdown in core growth and integration risks, Waters' multiple could come under pressure in the future. Additionally, there are concerns about the potential impact of market headwinds and funding on the company's Biosciences business, which could have a significant impact on its overall performance. However, the company has a strong management team with a track record of successfully turning around legacy assets and integrating large acquisitions.
This aggregate rating is based on analysts' research of Waters and is not a guaranteed prediction by Public.com or investment advice.
Waters (WAT) Analyst Forecast & Price Prediction
Start investing in Waters (WAT)
Order type
Buy in
Order amount
Est. shares
0 shares